Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 3,505 shares at $20.41 ($68K) on 2014-10-29, disclosed to the SEC on 2014-10-31.
Scheduled sale ($68k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.66 | 1,400 | $26K | 38.5% |
| 2 | $19.78 | 2,005 | $40K | 58.5% |
| 3 | $20.41 | 100 | $2K | 3.0% |
| Total | $19.35 avg | 3,505 | $68K | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-02-03 | $112K | — | Filing → |